Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.

ABSTRACT:

SUBMITTER: Sekeres MA 

PROVIDER: S-EPMC9119221 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature